PMID: 6107945Jan 1, 1980Paper

The comparison of the effects of DL-308, a potential new neuroleptic agent, and thioridazine on some psychological and physiological functions in healthy volunteers

Psychopharmacology
E SzabadiP Gaszner

Abstract

Eight healthy male volunteers participated in four experimental sessions in which they ingested either DL-308 (10 mg), DL-308 (20 mg), thioridazine (50 mg) or placebo. Drugs were allocated to subjects and sessions in a double-blind fashion according to a balanced cross-over design. Both DL-308 and thioridazine displayed sedative properties, as indicated by the sedated appearance of the subjects, by a decrease in subjectively rated alertness and by an impairment of performance on psychomotor tests. DL-308 appeared to be a more potent sedative than thioridazine. DL-308 (10 mg) caused an increase in subjectivey rated sweating and objectively measured heart rate, suggesting a sympathomimetic property for the drug. DL-308, similarly to thioridazine, had effects consistent with an alpha-adrenolytic action; both drugs caused miosis, hypotension and a decrease in salivation. The decrease in salivation may also be consistent with an anticholinergic effect. When equisedative doses of the two drugs were compared, DL-308 had a much smaller influence on autonomic functions than thioridazine. DL-308 had a faster time-course of action than thioridazine. Peak effects were attained 1-3 h post-drug and the effects almost completely dissipated wi...Continue Reading

References

Jan 1, 1979·Pharmacology & Therapeutics. Part B: General & Systematic Pharmacology·H R Bürki
Jul 1, 1978·British Journal of Clinical Pharmacology·C Maxwell
Dec 1, 1976·The British Journal of Psychiatry : the Journal of Mental Science·E SzabadiJ A Besson
Dec 1, 1973·Australian Veterinary Journal·R E Chapman
Jan 1, 1973·Acta Pharmacologica Et Toxicologica·I M NielsenA V Christensen
May 1, 1969·Archives of Ophthalmology·J M Sneddon, P Turner
Sep 1, 1980·British Journal of Clinical Pharmacology·S IskandarE Szabadi
Sep 1, 1955·Journal of Abnormal Psychology·J E DOPPELT, W L WALLACE
May 1, 1965·The American Journal of Psychiatry·T J MELLINGER
Jul 1, 1959·A.M.A. Archives of General Psychiatry·R E PECK

❮ Previous
Next ❯

Citations

Jan 1, 1985·Naunyn-Schmiedeberg's Archives of Pharmacology·A AssandriG Tuan
Jan 22, 1985·European Journal of Pharmacology·M W LobbezooJ M Zwagemakers
Jun 1, 1991·Pharmacology, Biochemistry, and Behavior·J BruhwylerM Mercier
Mar 22, 2001·British Journal of Clinical Pharmacology·S J de VisserJ M van Gerven
Dec 1, 1985·Pharmacological Research Communications·P PugnettiA Restelli
Sep 1, 1987·Acta Psychiatrica Scandinavica·A Nilsonne
Mar 1, 1988·Acta Psychiatrica Scandinavica·A Nilsonne
Feb 1, 1982·The Journal of Pharmacy and Pharmacology·D BaroneF Rodenghi
Feb 1, 1982·The Journal of Pharmacy and Pharmacology·P FosbraeyE S Johnson
Aug 1, 1984·British Journal of Clinical Pharmacology·N TheofilopoulosC M Bradshaw
Jan 1, 1982·Alcoholism, Clinical and Experimental Research·B Porjesz, H Begleiter
May 30, 1998·The International Journal of Neuroscience·H BahramaliJ Wright
Oct 20, 1998·The International Journal of Neuroscience·H BahramaliR Meares
Dec 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·D J King
Sep 1, 1984·The British Journal of Psychiatry : the Journal of Mental Science·T SilverstoneA Dubini
Oct 1, 1992·Journal of Speech and Hearing Research·D A Nelson, B P Kimberley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here